Europe Backs Celgene’s Pomalidomide And Aegerion’s Lomitapide
This article was originally published in The Pink Sheet Daily
Executive Summary
Positive opinions from Europe's top drug assessment panel in May have included a long-acting "biobetter" lipegfilgrastim from Teva, a once-weekly HGH injection from Biopartners GmbH, and a smallpox vaccine developed by Bavarian Nordic with funding from the U.S. BioShield program.